Recursion Pharmaceuticals (RXRX) 10-Q 13 Aug 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2021	Jul. 31, 2021
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-40323
Entity Registrant Name	Recursion Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4099738
Entity Address, Address Line One	41 S Rio Grande Street
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84101
City Area Code	385
Local Phone Number	269 - 0203
Title of 12(b) Security	Class A Common Stock, par value $0.00001
Trading Symbol	RXRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Central Index Key	0001601830
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Class A
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		159,015,551
Class B
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		9,467,883

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 632,738	$ 262,126
Restricted cash	10,232	5,041
Accounts receivable	49	156
Other current assets	4,616	2,155
Total current assets	647,635	269,478
Property and equipment, net	48,549	25,967
Intangible assets, net	2,338	2,490
Other non-current assets	68	650
Total assets	698,590	298,585
Current liabilities
Accounts payable	3,196	1,074
Accrued expenses and other liabilities	12,710	10,485
Current portion of unearned revenue	10,000	10,000
Current portion of notes payable	3,135	1,073
Current portion of lease incentive obligation	499	467
Total current liabilities	29,540	23,099
Deferred rent	2,819	2,674
Unearned revenue, net of current portion	11,667	16,667
Notes payable, net of current portion	9,423	11,414
Lease incentive obligation, net of current portion	2,427	2,708
Total liabilities	55,876	56,562
Commitments and contingencies (Note 6)
Convertible preferred stock (series A, A-1, B, C, and D), $0.00001 par value; 200,000,000 and 121,434,713 shares authorized as of June 30, 2021 and December 31, 2020, respectively; 0 and 112,088,065 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively; Liquidation preference of $0 and $450,850 as of June 30, 2021 and December 31, 2020, respectively	0	448,312
Stockholders’ equity (deficit)
Common stock (Class A and B), $0.00001 par value; 2,000,000,000 (Class A 1,989,032,117, Class B 10,967,883) and 188,400,000 shares authorized as of June 30, 2021 and December 31, 2020, respectively; 168,425,907 (Class A 158,958,024, Class B 9,467,883) and 22,314,685 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	2	0
Additional paid-in capital	930,431	7,312
Accumulated deficit	(287,719)	(213,601)
Total stockholders’ equity (deficit)	642,714	(206,289)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$ 698,590	$ 298,585

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Temporary Equity [Abstract]
Convertible preferred stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Convertible preferred stock, shares authorized (in shares)	200,000,000	121,434,713
Convertible preferred stock, shares issued (in shares)	0	112,088,065
Convertible preferred stock, shares outstanding (in shares)	0	112,088,065
Convertible preferred stock, liquidation preference	$ 0	$ 450,850
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized (in shares)	2,000,000,000	188,400,000
Common stock, shares issued (in shares)	168,425,907	22,314,685
Common sock, shares outstanding (in shares)	168,425,907	22,314,685
Class A
Common stock, shares authorized (in shares)	1,989,032,117
Common stock, shares issued (in shares)	158,958,024
Common sock, shares outstanding (in shares)	158,958,024
Class B
Common stock, shares authorized (in shares)	10,967,883
Common stock, shares issued (in shares)	9,467,883
Common sock, shares outstanding (in shares)	9,467,883

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue
Revenue	$ 2,549	$ 186	$ 5,111	$ 246
Operating expenses
Research and development	29,624	13,244	53,733	26,086
General and administrative	13,854	5,159	22,791	10,720
Total operating expenses	43,478	18,403	76,524	36,806
Loss from operations	(40,929)	(18,217)	(71,413)	(36,560)
Other loss, net	(2,472)	(726)	(2,705)	(807)
Net loss and comprehensive loss	(43,401)	(18,943)	(74,118)	(37,367)
Net loss and comprehensive loss	$ (43,401)	$ (18,943)	$ (74,118)	$ (37,367)
Per share data
Net loss per share of Class A and B common stock, basic (in dollars per share)	$ (0.31)	$ (0.88)	$ (0.91)	$ (1.73)
Net loss per share of Class A and B common stock, diluted (in dollars per share)	$ (0.31)	$ (0.88)	$ (0.91)	$ (1.73)
Weighted average shares outstanding, basic (in shares)	138,360,646	21,652,277	81,022,240	21,646,118
Weighted average shares outstanding, diluted (in shares)	138,360,646	21,652,277	81,022,240	21,646,118
Grant revenue
Revenue
Revenue	$ 49	$ 186	$ 111	$ 246
Operating revenue
Revenue
Revenue	$ 2,500	$ 0	$ 5,000	$ 0

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) (unaudited) - USD ($) $ in Thousands	Total	Series A and Series B Warrants	Convertible preferred stock	Common Stock (Class A and B)	Common Stock (Class A and B)Series A and Series B Warrants	Common Stock (Class A and B)Convertible preferred stock	Additional Paid-in-Capital	Additional Paid-in-CapitalSeries A and Series B Warrants	Additional Paid-in-CapitalConvertible preferred stock	Accumulated Deficit
Temporary equity, shares outstanding at beginning of period (in shares) at Dec. 31, 2019	75,189,517
Temporary equity, carrying amount attributable to parent at beginning of period at Dec. 31, 2019	$ 201,109
Temporary equity, shares outstanding at end of period (in shares) at Jun. 30, 2020	75,189,517
Temporary equity, carrying amount attributable to parent at end of period at Jun. 30, 2020	$ 201,109
Common stock, shares outstanding at beginning period (in shares) at Dec. 31, 2019				21,637,609
Total stockholders’ equity (deficit) at beginning of period at Dec. 31, 2019	(124,265)			$ 0			$ 2,330			$ (126,595)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(37,367)									(37,367)
Stock option exercises and other (in shares)				14,668
Stock option exercises and other	16						16
Stock-based compensation	2,178						2,178
Common stock, shares outstanding at end period (in shares) at Jun. 30, 2020				21,652,277
Total stockholders’ equity (deficit) at end of period at Jun. 30, 2020	$ (159,438)			$ 0			4,524			(163,962)
Temporary equity, shares outstanding at beginning of period (in shares) at Mar. 31, 2020	75,189,517
Temporary equity, carrying amount attributable to parent at beginning of period at Mar. 31, 2020	$ 201,109
Temporary equity, shares outstanding at end of period (in shares) at Jun. 30, 2020	75,189,517
Temporary equity, carrying amount attributable to parent at end of period at Jun. 30, 2020	$ 201,109
Common stock, shares outstanding at beginning period (in shares) at Mar. 31, 2020				21,652,277
Total stockholders’ equity (deficit) at beginning of period at Mar. 31, 2020	(141,387)			$ 0			3,632			(145,019)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(18,943)									(18,943)
Stock-based compensation	892						892
Common stock, shares outstanding at end period (in shares) at Jun. 30, 2020				21,652,277
Total stockholders’ equity (deficit) at end of period at Jun. 30, 2020	$ (159,438)			$ 0			4,524			(163,962)
Temporary equity, shares outstanding at beginning of period (in shares) at Dec. 31, 2020	112,088,065
Temporary equity, carrying amount attributable to parent at beginning of period at Dec. 31, 2020	$ 448,312
Increase (Decrease) in Temporary Equity [Roll Forward]
Conversion of preferred stock to common stock (in shares)	(112,088,065)
Conversion of preferred stock to common stock	$ (448,312)
Temporary equity, shares outstanding at end of period (in shares) at Jun. 30, 2021	0
Temporary equity, carrying amount attributable to parent at end of period at Jun. 30, 2021	$ 0
Common stock, shares outstanding at beginning period (in shares) at Dec. 31, 2020	22,314,685			22,314,685
Total stockholders’ equity (deficit) at beginning of period at Dec. 31, 2020	$ (206,289)			$ 0			7,312			(213,601)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(74,118)									(74,118)
Common stock issuance for initial public offering, net of issuance costs (in shares)				27,878,787
Common stock issuance for initial public offering, net of issuance costs	$ 462,354						462,353
Conversion of preferred stock to common stock (in shares)					129,963	115,598,018
Conversion of preferred stock to common stock		$ 2,340	$ 448,312			$ 1		$ 2,340	$ 448,311
Stock option exercises and other (in shares)	2,504,497			2,504,454
Stock option exercises and other	$ 2,977						2,977
Stock-based compensation	$ 7,138						7,138
Common stock, shares outstanding at end period (in shares) at Jun. 30, 2021	168,425,907			168,425,907
Total stockholders’ equity (deficit) at end of period at Jun. 30, 2021	$ 642,714			$ 2			930,431			(287,719)
Temporary equity, shares outstanding at beginning of period (in shares) at Mar. 31, 2021	112,088,065
Temporary equity, carrying amount attributable to parent at beginning of period at Mar. 31, 2021	$ 448,312
Increase (Decrease) in Temporary Equity [Roll Forward]
Conversion of preferred stock to common stock (in shares)	(112,088,065)
Conversion of preferred stock to common stock	$ (448,312)
Temporary equity, shares outstanding at end of period (in shares) at Jun. 30, 2021	0
Temporary equity, carrying amount attributable to parent at end of period at Jun. 30, 2021	$ 0
Common stock, shares outstanding at beginning period (in shares) at Mar. 31, 2021				24,036,725
Total stockholders’ equity (deficit) at beginning of period at Mar. 31, 2021	(233,031)			$ 0			11,287			(244,318)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(43,401)									(43,401)
Common stock issuance for initial public offering, net of issuance costs (in shares)				27,878,787
Common stock issuance for initial public offering, net of issuance costs	462,354			$ 1			462,353
Conversion of preferred stock to common stock (in shares)					129,963	115,598,018
Conversion of preferred stock to common stock		$ 2,340	$ 448,312			$ 1		$ 2,340	$ 448,311
Stock option exercises and other (in shares)				782,414
Stock option exercises and other	823						823
Stock-based compensation	$ 5,317						5,317
Common stock, shares outstanding at end period (in shares) at Jun. 30, 2021	168,425,907			168,425,907
Total stockholders’ equity (deficit) at end of period at Jun. 30, 2021	$ 642,714			$ 2			$ 930,431			$ (287,719)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net loss	$ (74,118)	$ (37,367)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,733	1,961
Stock-based compensation	7,138	2,034
Increase (Decrease) in Contract with Customer, Liability	(5,000)	0
Other, net	2,476	(144)
Changes in operating assets and liabilities:
Accounts receivable	98	142
Other assets	(2,460)	(850)
Accounts payable	2,122	92
Accrued development expense	606	(574)
Accrued expenses, deferred rent and other current liabilities	997	190
Net cash used in operating activities	(64,408)	(34,516)
Cash flows from investing activities
Purchases of property and equipment	(25,628)	(1,318)
Proceeds from note receivable	0	595
Net cash used in investing activities	(25,628)	(723)
Cash flows from financing activities
Proceeds from initial public offering of common stock, net of issuance costs	462,901	0
Proceeds from exercise of stock options	2,978	16
Repayment of long-term debt	(40)	(37)
Proceeds from convertible notes	0	6,400
Net cash provided by financing activities	465,839	6,379
Net change in cash, cash equivalents and restricted cash	375,803	(28,860)
Cash, cash equivalents and restricted cash, beginning of period	267,167	75,171
Cash, cash equivalents and restricted cash, end of period	642,970	46,311
Supplemental disclosure of non—cash investing and financing information
Conversion of preferred stock to common stock	448,312	0
Deferred issuance costs recorded in equity	547	0
Accrued property and equipment	763	11
Supplemental disclosure of cash flow information
Cash paid for interest	$ 540	$ 722

Description of the Business

Description of the Business	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Business	Description of the Business Recursion Pharmaceuticals, Inc. (Recursion, the Company, we or us) was originally formed as a limited liability company on November 4, 2013 under the name Recursion Pharmaceuticals, LLC. In September 2016, we converted to a Delaware corporation and changed our name to Recursion Pharmaceuticals, Inc. Recursion is a biotechnology company that combines automation, artificial intelligence, machine learning, in vivo validation capabilities and a highly cross-functional team to discover novel medicines that expand our collective understanding of biology. Recursion’s rich, relatable database of biological images generated in-house on the Company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. As of June 30, 2021, the Company had an accumulated deficit of $287.7 million. The Company expects to incur substantial operating losses in future periods and will require additional capital to advance its drug candidates. The Company does not expect to generate significant revenue until the Company successfully completes significant drug development milestones with its subsidiaries or in collaboration with third parties, which the Company expects will take a number of years. In order to commercialize its drug candidates, the Company or its partners need to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as the uncertainty of clinical trial outcomes, uncertainty of additional funding and a history of operating losses. The Company has funded its operations to date through the issuance of convertible preferred stock (see Note 7, “Convertible Preferred Stock” for additional information) and the issuance of Class A common stock in an Initial Public Offering (IPO), which was completed in April 2021 (see Note 8, “Common Stock” for additional details). Recursion will likely be required to raise additional capital. As of June 30, 2021, the Company did not have any unconditional outstanding commitments for additional funding. If the Company is unable to access additional funds when needed, it may not be able to continue the development of its products or the Company could be required to delay, scale back or abandon some or all of its development programs and other operations. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, could materially harm its business, financial condition and results of operations. The Company believes that the net proceeds from the IPO, together with the Company’s existing cash and cash equivalents and borrowings available to it, will be sufficient to fund the Company’s operating expenses and capital expenditures for at least the next 12 months.

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation Basis of Presentation The unaudited interim condensed consolidated financial statements of Recursion have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes for the year ended December 31, 2020 included in the Company’s final prospectus dated as of April 15, 2021 and filed with the SEC pursuant to Rule 424(b)(4) on April 16, 2021. In April 2021, the Company completed a 1.5-for-1 forward stock split of common and convertible preferred stock. All shares presented within these condensed consolidated financial statements were adjusted to reflect the forward stock split for all periods presented. See Note 8, “Common Stock” for additional details. In April 2021, the Company’s Board of Directors authorized two classes of common stock, Class A and Class B. Certain shares of Class A were exchanged for Class B on a one for one basis. The creation and issuance of the Class B common stock did not affect the loss per share for the Class A or Class B shares for any period. The Company presented the 2021 net loss per share amounts as if the authorization and exchange occurred as of the start of the 2021 reporting period. See Note 8, “Common Stock” for additional details. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, operating results and cash flows. Revenues and net loss for any interim period are not necessarily indicative of future or annual results. Emerging Growth Company The Company is an emerging growth company (EGC), as defined by the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). The JOBS Act exempts EGCs from being required to comply with new or revised financial accounting standards until private companies are required to comply. Recursion has elected to use the extended transition period for new or revised financial accounting standards. However, the Company may adopt certain new or revised accounting standards early. This may make comparisons of the Company’s financial statements with other public companies difficult because of the potential differences in accounting standards used. Recursion may remain an EGC until December 31, 2026, although if we: (1) become a “large accelerated filer;” (2) have annual gross revenues of $1.07 billion or more in any fiscal year; or (3) issue more than $1.0 billion of non-convertible debt over a three-year period, the Company would cease to be an EGC as of December 31 of the applicable year. Recent Accounting Pronouncements

Supplemental Financial Informat

Supplemental Financial Information	6 Months Ended
	Jun. 30, 2021
Supplemental Financial Information [Abstract]
Supplemental Financial Information	Supplemental Financial Information Property and Equipment June 30, December 31, (in thousands) 2021 2020 Lab equipment $ 25,562 $ 19,701 Leasehold improvements 13,312 13,792 Office equipment 20,005 1,075 Construction in progress 3,427 1,361 Property and equipment, gross 62,306 35,929 Less: Accumulated depreciation (13,757) (9,962) Property and equipment, net $ 48,549 $ 25,967 Depreciation expense on property and equipment was $2.4 million and $3.8 million during the three and six months ended June 30, 2021, respectively, and $1.0 million and $2.0 million during the three and six months ended June 30, 2020, respectively. For the six months ended June 30, 2021, the Company purchased a Dell EMC supercomputer for $17.9 million. The purchase was classified as office equipment in the above table. Accrued Expenses and Other Liabilities June 30, December 31, (in thousands) 2021 2020 Accrued compensation $ 4,396 $ 3,085 Accrued development expenses 2,895 2,289 Accrued early discovery expenses 1,113 338 Accrued other expenses 4,306 4,773 Accrued expense and other liabilities $ 12,710 $ 10,485 Interest Expense, net Three months ended June 30, Six months ended June 30, (in thousands) 2021 2020 2021 2020 Interest expense $ 2,501 $ 426 $ 2,750 $ 727 Interest income (29) (24) (45) (244) Interest expense, net $ 2,472 $ 402 $ 2,705 $ 483 For the three and six months ended June 30, 2021, interest expense primarily related to changes in fair value of the Series A and B warrants (see Note 10, “Stock-based Compensation” for additional details on the warrants). The Company also had expenses for the Midcap loan and tenant improvement allowance notes (see Note 5, “Notes Payable” for additional details.) Interest expense was included in “Other loss, net” on the Condensed Consolidated Statements of Operations and Comprehensive Loss.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The carrying amount of goodwill was $801 thousand as of June 30, 2021. There were no changes to the carrying amount of goodwill during the three and six months ended June 30, 2021. There was no goodwill balance outstanding during the three and six months ended June 30, 2020. As of June 30, 2021, there were no reductions in goodwill relating to impairment losses. Intangible Assets, Net The following table summarizes intangible assets: June 30, 2021 December 31, 2020 (in thousands) Gross carrying amount Accumulated Amortization Net carrying amount Gross carrying amount Accumulated Amortization Net carrying amount Definite-lived intangible asset $ 911 $ (278) $ 633 $ 911 $ (127) $ 784 Indefinite-lived intangible asset 904 — 904 904 — 904 Intangible assets, net $ 1,815 $ (278) $ 1,537 $ 1,815 $ (127) $ 1,688 Amortization expense was $76 thousand and $152 thousand during the three and six months ended June 30, 2021, respectively. There was no amortization expense during the three and six months ended June 30, 2020. Amortization expense was included in research and development in the Condensed Consolidated Statements of Operations and Comprehensive Loss. No definite-lived intangible asset impairment charges were recorded during

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Notes Payable	Notes Payable Midcap Financial In September 2019, the Company entered into a new Credit and Security Agreement with Midcap Financial Trust (Midcap) and the other lenders party thereto (the Midcap Loan Agreement). The Midcap Loan Agreement provides for a term loan facility that includes: i) an initial tranche of $11.9 million; and ii) a second tranche of up to $15.0 million, which if drawn would result in a maximum outstanding amount of $26.9 million. The Company used $11.2 million of the proceeds from the initial tranche to fully repay a previously outstanding term loan with Pacific Western Bank (Pacific). Proceeds from the term loans may be used for general corporate purposes. As of June 30, 2021 and December 31, 2020, the outstanding principal balance under the Midcap loan agreement was $11.9 million. Interest on the Midcap loan accrues on the principal amount outstanding at a floating per annum rate equal to the LIBOR rate (floor of 2.00%) plus 5.75% and is payable monthly in arrears. The Company is required to make interest-only payments from September 2019 to September 2021 and thereafter, 36 monthly principal payments of $330 thousand plus interest. The interest-only period will be extended an additional 12 months under certain conditions. The Company may voluntarily prepay the Midcap loan, subject to certain minimum repayment requirements and prepayment fees. The Midcap loan is subject to a mandatory prepayment under certain conditions. The debt is secured against substantially all of the Company’s assets. The Midcap Loan Agreement includes standard affirmative and restrictive covenants, including covenants limiting the ability of the Company and its subsidiaries to, among other things, dispose of assets, grant certain licenses, make investments, consummate mergers or acquisitions, incur debt, grant liens and make dividends or distributions, in each case subject to certain exceptions. The loan agreement also includes standard events of default, including, subject to grace periods in certain instances, payment defaults; breaches of covenants; breaches of representations and warranties; cross-defaults with certain other indebtedness; insolvency and bankruptcy defaults; a change of control of the Company or any subsidiary; or a material adverse change in the business, operations or conditions of the Company. Upon the occurrence of an event of default, Midcap may declare all outstanding obligations immediately due and payable, increase the applicable interest rate by 2% and take such other actions as set forth in the Midcap Loan Agreement. As of June 30, 2021 and 2020, the Company was in compliance with all debt covenants. In 2019, the Company paid fees of approximately $298 thousand in connection with the origination of the Midcap Loan Agreement. These fees were deferred and recorded as a direct deduction from the carrying value of the loan payable and are being amortized to interest expense over the remaining term of the agreement. Pacific Western In May 2018, Pacific issued a standby letter of credit of $3.8 million for the benefit of the Company’s landlord, securing certain Company obligations relating to tenant improvements. This letter of credit was transferred to J.P. Morgan during the three and six months ended June 30, 2021. See Note 14, “Fair Value Measurements” for additional details. As of December 31, 2020, the outstanding letter of credit was $3.8 million, for which the Company held $4.0 million of restricted cash as collateral. Convertible Notes For the six months ended June 30, 2020, the Company issued convertible promissory notes for an aggregate principal amount of $6.4 million. Under certain conditions, the principal was convertible into an amount of equity with a fair value that exceeded the amount of the notes’ principal on the conversion date. This feature of the notes was accounted for separately at fair value as a derivative liability. Changes in the fair value of the derivative were recorded in “Other loss, net” in the Condensed Consolidated Statements of Operations and Comprehensive Loss and were $323 thousand during the three and six months ended June 30, 2020. In September 2020, these notes converted to 1,203,231 shares of Series D Preferred Stock. Upon conversion of the notes, the Company recorded the $1.6 million fair value of the derivative liability as equity on the Condensed Consolidated Balance Sheet. Notes Payable for Tenant Improvement Allowance In 2018, the Company borrowed $992 thousand, which was available as part of the Station 41 lease, from its landlord for use on tenant improvements (see Note 6, “Commitments and Contingencies” for additional details). Under the terms of the lease, the note will be repaid over a 10-year period at an 8% interest rate. Notes payable under the Midcap loan agreement and for tenant improvement allowances, including accrued interest, consisted of the following: June 30, December 31, (in thousands) 2021 2020 Current portion of notes payable $ 3,135 $ 1,073 Long-term portion of notes payable 9,595 11,615 Less: unamortized issuance costs (172) (201) Notes payable, net $ 12,558 $ 12,487 The following table presents information regarding the Company’s debt principal repayment obligations as of June 30, 2021: (in thousands) Amount 2021 $ 1,033 2022 4,052 2023 4,059 2024 3,059 2025 112 Thereafter 346 Total debt principal payments $ 12,661

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease Obligations The Company has entered into various long-term real estate leases primarily related to office, research and development (R&D) and operating activities. For the three and six months ended June 30, 2021, total rent expense was $1.4 million and $2.7 million, respectively. For the three and six months ended June 30, 2020, total rent expense was $1.1 million and $2.1 million, respectively. The Komas, Station 41 and Milpitas leases described below are classified as operating leases. Komas Lease In August 2016, the Company entered into a new facilities lease, with the right of use and payments beginning in January 2017. The term of the lease is 7 years. This lease includes provisions for escalating rent payments. Rent expense is recognized on a straight-line basis over the term of the lease. This lease included an allowance for tenant improvements. Tenant improvements were recorded as property and equipment and are being depreciated over the term of the lease. In conjunction with the allowance for tenant improvements, the Company recorded a lease incentive obligation of $847 thousand which is being amortized over the term of the lease as a reduction to rent expense. As of June 30, 2021, the related unamortized lease incentive obligation was $313 thousand. Station 41 Lease In August 2017, the Company entered into a new facilities lease, with the right of use beginning in December 2017 and payments beginning in June 2018. The term of the lease is 10 years, with one five-year renewal option exercisable by the Company. This lease includes provisions for escalating rent payments. Rent expense is recognized straight-line over the term of the lease. This lease included an allowance for tenant improvements of $4.0 million, the full amount of which was drawn in 2017. Tenant improvements were recorded as property and equipment and are being depreciated over the remaining term of the lease. In conjunction with the allowance for tenant improvements, the Company recorded a leasehold obligation, which is being amortized over the term of the lease as a reduction to rent expense. As of June 30, 2021, the related unamortized lease incentive obligation was $2.6 million. In 2018, the Company elected to draw an additional tenant improvement loan of $992 thousand available under the Station 41 lease. This loan is incorporated into and acts to increase the base rent over the remaining life of the lease. The increase in rent includes a charge for interest, which accrues on the principal amount outstanding at a rate equal to 8%. The Company accounts for this additional tenant improvement loan as a note payable on the Condensed Consolidated Balance Sheets with the current portion included in the Current Portion of Notes Payable. In 2019, the Company amended the Station 41 Lease to include additional space in the conjoining unit with the right to use the new space beginning in June 2020 for an additional 7 years. This amendment for the extra space includes provisions for escalating rent payments. Rent expense is recognized straight-line over the term of the lease. In January 2021, the Company again amended the Station 41 Lease, increasing the leased square footage by 91,478 square feet. This amendment includes provisions for escalating rent, has a 10 year term and additional total minimum payments of $32.4 million. This lease included a tenant improvement allowance of up to approximately $10.1 million. Milpitas Lease In August 2019, the Company entered into a new facilities lease, with the right of use and payments beginning in August 2019. The term of the lease is 9 years. This lease includes provisions for escalating rent payments. Rent expense is recognized on a straight-line basis over the term of the lease. Future Minimum Lease Payments Future minimum commitments as of June 30, 2021 under the Company’s lease agreements are as follows: (in thousands) Amount 2021 $ 1,952 2022 4,963 2023 7,344 2024 7,371 2025 7,560 Thereafter 33,214 Total Minimum Payments $ 62,404 Contract Obligations In the normal course of business, the Company enters into contracts with clinical research organizations, drug manufacturers and other vendors for preclinical and clinical research studies, research and development supplies and other services and products for operating purposes. These contracts generally provide for termination on notice and are cancellable contracts. Indemnification The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company’s request in such capacity. The Company purchases directors and officers liability insurance coverage that provides for reimbursement to the Company for covered obligations and this is intended to limit the Company’s exposure and enable it to recover a portion of any amounts it pays under its indemnification obligations. The Company had no liabilities recorded for these agreements as of June 30, 2021 and December 31, 2020, as no amounts in excess of insurance coverage are probable or estimable. Employee Agreements The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including accelerated vesting of equity incentives. Legal Matters

Convertible Preferred Stock

Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2021
Temporary Equity [Abstract]
Convertible Preferred Stock	Convertible Preferred Stock The Company has issued preferred stock as part of various financing events. In April 2021, all outstanding shares of convertible preferred stock converted into 115,598,018 shares of Class A common stock as part of the IPO (see Note 8, “Common Stock” for additional details on the IPO). There was no convertible preferred stock outstanding as of June 30, 2021. No new convertible preferred stock was issued during the three and six months ended June 30, 2021 and 2020. As of June 30, 2020, there were no cumulative dividends owed or in arrears on the preferred stock. Convertible Preferred Stock consisted of the following as of December 31, 2020: (in thousands except share data) Preferred Shares Authorized Preferred Shares Issued and Outstanding Carrying Value Liquidation Preferences Shares of Common Stock Issuable Upon Conversion Series A 30,078,402 29,965,754 $ 21,281 $ 21,281 29,965,754 Series A-1 4,975,521 4,975,520 — — 4,975,520 Series B 21,497,667 21,471,898 59,913 60,000 21,471,898 Series C 18,956,354 18,776,345 119,915 122,058 22,286,298 Series D 45,926,769 36,898,548 247,203 247,511 36,898,548 Total convertible preferred stock 121,434,713 112,088,065 $ 448,312 $ 450,850 115,598,018 Balance Sheet Classification

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Common Stock	Common Stock Each share of Class A common stock entitles the holder to one vote per share and each share of Class B common stock entitles the holder to 10 votes per share on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company’s board of directors. As of June 30, 2021 and December 31, 2020, no dividends had been declared. Initial Public Offering On April 20, 2021, the Company closed its IPO and issued 27,878,787 shares of its common stock at a price of $18.00 per share for net proceeds of $462.4 million, after deducting underwriting discounts and commissions of $35.1 million and other offering costs of $4.3 million. In connection with the IPO, all shares of Series A, A-1, B, C and D convertible preferred stock converted into 115,598,018 shares of Class A common stock. Stock Split In April 2021, the Board of Directors approved a 1.5-for-1 forward stock split of the Company’s common and convertible preferred stock. Each shareholder of record on April 9, 2021 received 1.5 shares for each then-held share. The split proportionally increased the authorized shares and did not change the par values of the Company’s stock. The split affected all stockholders uniformly and did not affect any stockholder's ownership percentage of the Company's shares of common stock. All shares and per share amounts presented within these Condensed Consolidated Financial Statements were adjusted to reflect the forward stock split for all periods presented. Class A and B Common Shares Authorization In April 2021, the Company’s Board of Directors authorized two classes of common stock, Class A and Class B. The rights of the holders of Class A and B common stock are identical, except with respect to voting and conversion. Each share of Class A common stock is entitled to one vote per share. Each share of Class B common stock is entitled to 10 votes per share and is convertible at any time into one share of Class A common stock. All Class B common stock is held by Christopher Gibson, Ph.D., our Chief Executive Officer (CEO), or his affiliate. As of June 30, 2021, Dr. Gibson and his affiliate held outstanding shares of Class B common stock representing approximately 38% of the voting power of the Company’s outstanding shares. This voting power may increase over time as Dr. Gibson vests in and exercises equity awards outstanding. If all the equity awards held by Dr. Gibson had been fully vested and exercised and exchanged for shares of Class B common stock as of June 30, 2021, Dr. Gibson and his affiliate would hold approximately 41% of the voting power of the Company’s outstanding shares. As a result, Dr. Gibson will be able to significantly influence any action requiring the approval of Recursion stockholders, including the election of the board of directors; the adoption of amendments to the Company’s certificate of incorporation and bylaws; and the approval of any merger, consolidation, sale of all or substantially all of the Company’s assets, or other major corporate transaction.

Collaborative and Other Researc

Collaborative and Other Research and Development Contracts	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative and Other Research and Development Contracts	Collaborative and Other Research and Development Contracts Bayer AG In August 2020, the Company entered into a Research Collaboration and Option Agreement (the Bayer Agreement) with Bayer AG (Bayer) for a five-year term pursuant to which the Company and Bayer may initiate approximately 10 research projects related to fibrosis across multiple organ systems, including the lung, liver and heart. Under the agreement, the Company contributed compounds from our proprietary library and Bayer contributed compounds from its proprietary library and will contribute scientific expertise throughout the collaboration. Under the terms of the agreement, the Company received a non-refundable upfront payment of $30.0 million, which was recorded as unearned revenue on the Condensed Consolidated Balance Sheet. The Company determined that it has one performance obligation under the agreement, which is to perform research and development services for Bayer. Recursion determined the transaction price to be the $30.0 million upfront payment received and allocated the amount to the single performance obligation. The Company is recognizing the revenue over time using a cost-based input method, based on labor costs incurred to perform the research and development services. This method of recognizing revenue requires the Company to make estimates of the total costs to provide the services required under the performance obligation. A significant change in these estimates could have a material effect on the timing and amount of revenue recognized in future periods. For the three and six months ended June 30, 2021, the Company recognized $2.5 million and $5.0 million, respectively, of revenue resulting from the collaboration. There was $10.0 million and $11.7 million of current and non-current unearned revenue, respectively, remaining as of June 30, 2021. The allocation of unearned revenue between current and non-current is based on Recursion’s estimates of when the Company expects to incur the related costs. Under each research project, the Company will work with Bayer to identify potential candidates for development. Under the agreement, Bayer has the first option for licenses to potential candidates. Each such license could potentially result in option exercise fees and development and commercial milestone payments payable to the Company, with an aggregate value of up to approximately $100.0 million (for an option on a lead series) or up to approximately $120.0 million (for an option on a development candidate), as well as tiered royalties for each such license, ranging from low- to mid-single digit percentages of sales, depending on commercial success. The National Institute of Health During the year ended December 31, 2018, the Company was awarded a grant by the National Institute of Health, which included potential funding of $1.4 million. Revenue recognized related to this grant during the three and six months ended June 30, 2021 was $49 thousand and $111 thousand, respectively. Revenue recognized during the three and six months ended June 30, 2020 was $186 thousand and $246 thousand, respectively. As of June 30, 2021, $346 thousand of the potential funding remained available.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table presents the classification of stock-based compensation expense for stock options and restricted stock units (RSUs) for employees and non-employees within the Condensed Consolidated Statements of Operations and Comprehensive Loss: Three months ended June 30, Six months ended June 30, (in thousands) 2021 2020 2021 2020 Research and development $ 1,067 $ 288 $ 1,696 $ 976 General and administrative 3,910 481 4,980 1,058 Total $ 4,977 $ 769 $ 6,676 $ 2,034 Key Personnel Incentive Plan In November 2013, the Company adopted the Key Personnel Incentive Plan (the KPI Plan). The KPI Plan provides for the grant of restricted units and non-statutory option awards to employees, non-employee directors and consultants of the Company. As of June 30, 2021, there were no shares of common stock available for grant under the KPI Plan. 2016 Equity Incentive Plan In August 2016, the Board of Directors and the stockholders of the Company adopted the 2016 Equity Incentive Plan. Under the 2016 Plan, 25,686,958 shares of common stock were reserved. As of June 30, 2021 there were no shares of common stock available for grant under the 2016 Equity Incentive Plan. 2021 Equity Incentive Plan In April 2021, the Board of Directors and the stockholders of the Company adopted the 2021 Equity Incentive Plan (the 2021 Plan). Under the 2021 Plan, 16,186,000 shares of Class A common stock were reserved. Additionally, shares were reserved for all outstanding awards under the 2016 Plan. The Company may grant stock options, RSUs, stock appreciation rights, restricted stock awards and other forms of stock-based compensation. As of June 30, 2021, 15,507,871 shares of Class A common stock were available for grant. Stock Options Stock options generally vest over four years and expire no later than 10 years from the date of grant. Stock option activity during the six months ended June 30, 2021 was as follows: (in thousands except share data) Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value Outstanding as of December 31, 2020 20,937,443 $ 1.85 8.5 $ 12,956 Granted 2,722,835 10.02 Cancelled (680,666) 2.28 Exercised (2,504,497) 1.18 9,629 Outstanding as of June 30, 2021 20,475,115 $ 2.84 8.6 $ 647,397 Exercisable as of June 30, 2021 7,146,350 $ 1.79 7.6 $ 213,533 The fair value of options granted to employees is calculated on the grant date using the Black-Scholes option valuation model. The weighted-average grant-date fair values of stock options granted during the six months ended June 30, 2021 and 2020 were $5.96 and $1.49, respectively. The following weighted-average assumptions were used to calculate the grant-date fair value of employee stock options: Six months ended June 30, 2021 2020 Expected term (in years) 6.2 6.2 Expected volatility 66 % 65 % Expected dividend yield — — Risk-free interest rate 0.97 % 1.00 % In February 2021, the Company granted 150,000 shares of stock options with a performance and service condition that had a fair value of $358 thousand. The grant was fully expensed during the three months ended June 30, 2021 as the performance and service conditions were met. In March 2020, the Company granted 1,500,000 shares of stock options with performance, market and service conditions. At grant date, the Company estimated that the fair value of the options was approximately $2.0 million. For the three and six months ended June 30, 2021, $1.6 million of expense was recorded as several of the conditions were met. For the three and six months ended June 30, 2020, no expense was recorded as the performance conditions were not considered probable. During the years ended December 31, 2020 and 2017, the Company granted options to purchase 120,000 and 330,000 shares, respectively, of common stock to non-employee consultants. These options were granted in exchange for consulting services and vest over a period that approximates the term of the services to be provided by the Company. The fair value of the options granted prior to 2020 were remeasured in each period until they were fully vested. Following the adoption of ASU 2018-07 on January 1, 2020, the fair value of options granted to non-employees were no longer remeasured subsequent to the grant date. The fair value of each option on the date of grant was calculated using the Black-Scholes option model. There were no grants to non-employee consultants during the three and six months ended June 30, 2021 and 2020. As of June 30, 2021, $28.6 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next 3 years. RSUs In April 2021, Recursion redesigned certain aspects of its long-term incentive program. As a result, equity awards granted to employees since the redesign generally consist of a combination of stock options and RSUs. RSUs awarded to employees pursuant to the 2021 Plan generally vest over four years. The weighted-average grant-date fair value of RSUs generally is determined based on the number of units granted and the quoted price of Recursion’s common stock on the date of grant. The following table summarizes Recursion’s RSU activity during the six months ended June 30, 2021: Stock units Weighted-average grant date fair value Outstanding as of December 31, 2020 — $ — Granted 76,762 30.42 Vested — — Forfeited — — Outstanding as of June 30, 2021 76,762 $ 30.42 As of June 30, 2021, $2.1 million of unrecognized compensation cost related to RSUs is expected to be recognized as expense over approximately the next 2.75 years. Employee share purchase plan (ESPP) In April 2021, the Board of Directors and stockholders of the Company adopted the 2021 Employee Stock Purchase Plan (the 2021 ESPP). Under the 2021 ESPP, 3,238,000 shares of Class A common stock were reserved. The 2021 ESPP has consecutive six month offering periods. The offering periods will be scheduled to start on the first trading day on or after May 20 and November 20 of each year, except the first offering period, which commenced on the Plan Effectiveness Date and will end on the last trading day on or after November 20, 2021. The second offering period will commence on the first trading day on or after November 20, 2021. The per share purchase price will be 85% of the lower of the fair market value on 1) the first trading day of the offering period or 2) the exercise date. Fair value of the ESPP grants are measured at grant date. The fair value is determined considering the purchase discount and the fair value of the look-back feature. Black-Scholes pricing models are used to calculate the fair value of the look-back feature. The weighted-average assumptions used in the Black-Scholes models were as follows: Three months ended Six months ended June 30, 2021 Expected term (in years) 0.6 0.6 Expected volatility 69 % 69 % Expected dividend yield — — Risk-free interest rate 0.04 % 0.04 % As of June 30, 2021, no shares have been issued under the 2021 ESPP. For the three and six months ended June 30, 2021, Recursion recognized expense of $216 thousand for the 2021 ESPP. As of June 30, 2021, $407 thousand of unrecognized compensation cost related to the 2021 ESPP is expected to be recognized as expense over approximately the next 5 months. Warrants In connection with the execution of the Pacific loan agreement (see Note 5, “Notes Payable” for additional details), the Company issued to Pacific fully vested warrants to purchase 84,486 Series A Preferred Stock (Series A warrants) at a purchase price of $0.71 per share. In May 2017, the Company drew on additional borrowing capacity under the Pacific loan agreement, which required the Company to issue additional fully vested warrants for 28,161 Series A Preferred Stock at a purchase price of $0.71 per share. These Series A warrants were exercised in April 2021. As of December 31, 2020, their fair value was $77 thousand. In July 2018, the Company drew on additional borrowing capacity under an amended agreement. This required the Company to issue fully vested warrants to purchase 25,762 Series B Preferred Stock (Series B warrants) at a purchase price of $2.79 per share. These Series B warrants were exercised in April 2021. As of December 31, 2020, their fair value was $48 thousand. In January 2020, the Company issued warrants to purchase 180,000 shares of Series C Preferred Stock (Series C warrants) at a purchase price of $6.51 per share as part of a services agreement. The warrants vest ratably over 18 months. The Series C warrants remained outstanding and 170,000 were vested and exercisable as of June 30, 2021. The grant date fair value was $4.10 per share. As of June 30, 2021, $35 thousand of unrecognized compensation cost related to the unvested warrants is expected to be recognized over 1 month. The FASB has issued accounting guidance on the classification of freestanding warrants and other similar instruments on shares that are redeemable (either puttable or mandatorily redeemable). The guidance requires liability classification for certain warrants that are exercisable into convertible preferred stock. The initial fair values of Series A and B warrants were recorded as debt issuance costs, which resulted in a reduction in the carrying value of the debt and subsequent accretion. The Company remeasured the Series A and B warrants on each Condensed Consolidated Balance Sheet date. The change in valuation was recorded in the Condensed Consolidated Statements of Operations and Comprehensive Loss in “Other loss, net.” The liability was recorded to equity upon the exercise of the Series A and B warrants. The Series C warrants’ compensation expense is being recorded in general and administrative expense ratably over the requisite service period based on the award’s fair value at the date of grant. These warrants were classified as equity as they were issued to non-employees for services and the convertible preferred stock was not redeemable, except in the event of a deemed liquidation event, which was not considered probable. The following is a summary of the changes in the Company’s Series A and B warrant liability balance during the six months ended June 30, 2021 and 2020: (in thousands) Balance as of December 31, 2019 $ 128 Net increase in fair value of warrants 5 Balance as of June 30, 2020 $ 133 Balance as of December 31, 2020 $ 125 Increase in fair value of warrants 2,215 Recorded in equity upon exercise (2,340) Balance as of June 30, 2021 $ —

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2021
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Benefit PlansThe Company has an employee benefit plan under Section 401(k) of the Internal Revenue Code. The plan allows employees to make contributions up to a specified percentage of their compensation. The Company is currently contributing up to 4% of employee base salary, by matching 100% of the first 4% of annual base salary contributed by each employee. Employer expenses were $372 thousand and $653 thousand during the three and six months ended June 30, 2021, respectively. For the three and six months ended June 30, 2020, employer expenses were $201 thousand and $400 thousand, respectively.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company did not record any income tax expense during the three and six months ended June 30, 2021 and 2020. The Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. Valuation allowances are recorded when the expected realization of the deferred tax assets does not meet a “more likely than not” criterion. Realization of the Company’s deferred tax assets are dependent upon the generation of future taxable income, the amount and timing of which are uncertain. Net operating loss carryforwards (NOLs) and tax credit carry-forwards are subject to review by the Internal Revenue Service (IRS) and may become subject to annual limitations due to ownership changes that have occurred previously or that could occur in the future under Section 382 of the Internal Revenue Code. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. Any limitation may result in expiration of a portion of the NOLs or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share For the three and six months ended June 30, 2021, Recursion calculated net loss per share of Class A and Class B common stock using the two-class method. Basic net loss per share is computed using the weighted-average number of shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares and the effect of potentially dilutive securities outstanding during the period. Potentially dilutive securities consist of stock options and other contingently issuable shares. For periods presented in which the Company reports a net loss, all potentially dilutive shares are anti-dilutive and as such are excluded from the calculation. For the three and six months ended June 30, 2021, the Company reported a net loss and therefore basic and diluted loss per share are the same. The rights, including the liquidation and dividend rights, of the holders of the Company’s Class A and Class B common stock are identical, except with respect to voting. As a result, the undistributed earnings for each period are allocated based on the contractual participation rights of the Class A and Class B common shares as if the earnings for the period had been distributed. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis and the resulting amount per share for Class A and Class B common stock was the same for three and six months ended June 30, 2021. Recursion issued certain convertible preferred stock that were outstanding until April 2021 and was concluded to be participating securities. For the three and six months ended June 30, 2020, there was only one class of common stock outstanding. Due to the presence of participating securities, Recursion calculated net loss per share for the three and six months ended June 30, 2020 using the more dilutive of the treasury stock or the two-class method. For periods presented in which the Company reports a net loss, the losses are not allocated to the participating securities. As the Company reported a net loss during the three and six months ended June 30, 2020, diluted net loss per share was the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The preferred stock converted to common stock in April 2021 as part of the Company’s IPO. See Note 8, “Common stock” for additional details. The following tables set forth the computation of basic and diluted net loss per share of Class A and Class B common stock during 2021: Three months ended Six months ended June 30, 2021 June 30, 2021 (in thousands, except share amount) Class A Class B Class A Class B Numerator: Allocation of undistributed earnings $ (40,432) $ (2,970) $ (65,457) $ (8,661) Denominator: Weighted average common shares outstanding 128,892,763 9,467,883 71,554,357 9,467,883 Net loss per share, basic and diluted $ (0.31) $ (0.31) $ (0.91) $ (0.91) The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: Three months ended Six months ended June 30, 2021 June 30, 2021 Class A Class B Class A Class B Convertible preferred stock 25,406,158 — 70,001,023 — Stock options and RSUs 17,115,903 — 15,445,067 — Warrants 178,208 — 193,773 — ESPP 13,334 — — — Total 42,713,603 — 85,639,863 — The following table sets forth the computation of basic and diluted net loss per share during 2020: Three months ended Six months ended (in thousands, except share amounts) June 30, 2020 Numerator: Net loss $ (18,943) $ (37,367) Denominator: Weighted average common shares outstanding 21,652,277 21,646,118 Net loss per share, basic and diluted $ (0.88) $ (1.73) The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: Three months ended Six months ended June 30, 2020 Convertible preferred stock 78,699,470 78,699,470 Stock options 4,557,396 4,087,585 Warrants 194,037 183,807 Total 83,450,903 82,970,862

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The fair value hierarchy consists of the following three levels: • Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access; • Level 2 — Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and • Level 3 — Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company's management about the assumptions market participants would use in pricing the asset or liability. As of June 30, 2021 and December 31, 2020, cash and cash equivalents (including restricted cash) included bank deposits held in checking and savings accounts. The Company is required to maintain a balance in a collateralized account to secure the Company’s credit cards. Additionally, the Company holds restricted cash related to an outstanding letter of credit issued by J.P. Morgan, which was obtained to secure certain Company obligations relating to tenant improvements. The Company measured the Series A and B preferred stock warrant liabilities at fair value using a Black-Scholes option-pricing model. See Note 10, “Stock-based Compensation” for details on the valuation of the warrant liabilities and a reconciliation of the balance. The following tables summarize the Company’s assets and liabilities that are measured at fair value on a recurring basis: Basis of fair value measurement (in thousands) June 30, 2021 Level 1 Level 2 Level 3 Assets Cash and equivalents $ 632,738 $ 632,738 $ — $ — Restricted cash 10,232 10,232 — — Total assets $ 642,970 $ 642,970 $ — $ — Basis of fair value measurement (in thousands) December 31, 2020 Level 1 Level 2 Level 3 Assets Cash and equivalents $ 262,126 $ 262,126 $ — $ — Restricted cash 5,041 5,041 — — Total assets $ 267,167 $ 267,167 $ — $ — Liabilities Warrant liability $ 125 $ — $ — $ 125 Total liabilities $ 125 $ — $ — $ 125 In addition to the financial instruments that are recognized at fair value on the Condensed Consolidated Balance Sheets, the Company has certain financial instruments that are recognized at amortized cost or some basis other than fair value. The carrying amount of these instruments are considered to be representative of their approximate fair values. The following tables summarize the Company’s financial instruments that are not measured at fair value: Book values Fair values (in thousands) June 30, 2021 December 31, 2020 June 30, 2021 December 31, 2020 Liabilities Current portion of notes payable $ 3,135 $ 1,073 $ 3,135 $ 1,073 Notes payable, net of current portion 9,423 11,414 9,423 11,414 Total liabilities $ 12,558 $ 12,487 $ 12,558 $ 12,487

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions On December 5, 2017, the Company entered into a loan agreement with its CEO to provide a loan of $595 thousand. The loan had a seven-year term. As of June 30, 2021 and 2020, no amount remained outstanding on the loan as the balance was fully paid during the six months ended June 30, 2020.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Midcap Financial debt extinguishmentIn July 2021, the Company paid the balance due on the loan outstanding with Midcap. The total amount paid was $12.7 million. See Note 5, “Notes Payable” for additional details on the Midcap loan.

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of presentation and emerging growth company	Basis of Presentation The unaudited interim condensed consolidated financial statements of Recursion have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes for the year ended December 31, 2020 included in the Company’s final prospectus dated as of April 15, 2021 and filed with the SEC pursuant to Rule 424(b)(4) on April 16, 2021. In April 2021, the Company completed a 1.5-for-1 forward stock split of common and convertible preferred stock. All shares presented within these condensed consolidated financial statements were adjusted to reflect the forward stock split for all periods presented. See Note 8, “Common Stock” for additional details. In April 2021, the Company’s Board of Directors authorized two classes of common stock, Class A and Class B. Certain shares of Class A were exchanged for Class B on a one for one basis. The creation and issuance of the Class B common stock did not affect the loss per share for the Class A or Class B shares for any period. The Company presented the 2021 net loss per share amounts as if the authorization and exchange occurred as of the start of the 2021 reporting period. See Note 8, “Common Stock” for additional details. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, operating results and cash flows. Revenues and net loss for any interim period are not necessarily indicative of future or annual results. Emerging Growth Company The Company is an emerging growth company (EGC), as defined by the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). The JOBS Act exempts EGCs from being required to comply with new or revised financial accounting standards until private companies are required to comply. Recursion has elected to use the extended transition period for new or revised financial accounting standards. However, the Company may adopt certain new or revised accounting standards early. This may make comparisons of the Company’s financial statements with other public companies difficult because of the potential differences in accounting standards used.
Recent accounting pronouncements	Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases - Topic 842 (ASU 2016-02). Under ASC 842, the Company will be required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) on its balance sheet at the commencement date of each lease. ASU 842 is effective for annual and interim periods beginning on or after December 15, 2021 and early adoption is permitted. The Company must adopt the standard using the modified retrospective approach either: (1) as of the earliest period presented and through the comparative periods in the entity’s financial statements or (2) as of the effective date of ASC 842, with a cumulative-effect adjustment to equity. The Company expects the adoption to materially increase assets and liabilities on the Condensed Consolidated Balance Sheets related to those leases classified as operating and not recognized on the Balance Sheets under current GAAP. The Company is continuing to evaluate the effect that ASU 842 will have on its consolidated financial statements and related disclosures. The Company will adopt the new standard on January 1, 2022.

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	6 Months Ended
	Jun. 30, 2021
Supplemental Financial Information [Abstract]
Schedule of property and equipment	Property and Equipment June 30, December 31, (in thousands) 2021 2020 Lab equipment $ 25,562 $ 19,701 Leasehold improvements 13,312 13,792 Office equipment 20,005 1,075 Construction in progress 3,427 1,361 Property and equipment, gross 62,306 35,929 Less: Accumulated depreciation (13,757) (9,962) Property and equipment, net $ 48,549 $ 25,967
Schedule of accrued expenses and other liabilities	Accrued Expenses and Other Liabilities June 30, December 31, (in thousands) 2021 2020 Accrued compensation $ 4,396 $ 3,085 Accrued development expenses 2,895 2,289 Accrued early discovery expenses 1,113 338 Accrued other expenses 4,306 4,773 Accrued expense and other liabilities $ 12,710 $ 10,485
Interest income and expense disclosure	Interest Expense, net Three months ended June 30, Six months ended June 30, (in thousands) 2021 2020 2021 2020 Interest expense $ 2,501 $ 426 $ 2,750 $ 727 Interest income (29) (24) (45) (244) Interest expense, net $ 2,472 $ 402 $ 2,705 $ 483

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of finite-lived intangible assets	The following table summarizes intangible assets: June 30, 2021 December 31, 2020 (in thousands) Gross carrying amount Accumulated Amortization Net carrying amount Gross carrying amount Accumulated Amortization Net carrying amount Definite-lived intangible asset $ 911 $ (278) $ 633 $ 911 $ (127) $ 784 Indefinite-lived intangible asset 904 — 904 904 — 904 Intangible assets, net $ 1,815 $ (278) $ 1,537 $ 1,815 $ (127) $ 1,688
Schedule of indefinite-lived intangible assets	The following table summarizes intangible assets: June 30, 2021 December 31, 2020 (in thousands) Gross carrying amount Accumulated Amortization Net carrying amount Gross carrying amount Accumulated Amortization Net carrying amount Definite-lived intangible asset $ 911 $ (278) $ 633 $ 911 $ (127) $ 784 Indefinite-lived intangible asset 904 — 904 904 — 904 Intangible assets, net $ 1,815 $ (278) $ 1,537 $ 1,815 $ (127) $ 1,688

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Schedule of debt	Notes payable under the Midcap loan agreement and for tenant improvement allowances, including accrued interest, consisted of the following: June 30, December 31, (in thousands) 2021 2020 Current portion of notes payable $ 3,135 $ 1,073 Long-term portion of notes payable 9,595 11,615 Less: unamortized issuance costs (172) (201) Notes payable, net $ 12,558 $ 12,487
Schedule of maturities of long-term debt	The following table presents information regarding the Company’s debt principal repayment obligations as of June 30, 2021: (in thousands) Amount 2021 $ 1,033 2022 4,052 2023 4,059 2024 3,059 2025 112 Thereafter 346 Total debt principal payments $ 12,661

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments	Future minimum commitments as of June 30, 2021 under the Company’s lease agreements are as follows: (in thousands) Amount 2021 $ 1,952 2022 4,963 2023 7,344 2024 7,371 2025 7,560 Thereafter 33,214 Total Minimum Payments $ 62,404

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2021
Temporary Equity [Abstract]
Schedule of temporary equity	Convertible Preferred Stock consisted of the following as of December 31, 2020: (in thousands except share data) Preferred Shares Authorized Preferred Shares Issued and Outstanding Carrying Value Liquidation Preferences Shares of Common Stock Issuable Upon Conversion Series A 30,078,402 29,965,754 $ 21,281 $ 21,281 29,965,754 Series A-1 4,975,521 4,975,520 — — 4,975,520 Series B 21,497,667 21,471,898 59,913 60,000 21,471,898 Series C 18,956,354 18,776,345 119,915 122,058 22,286,298 Series D 45,926,769 36,898,548 247,203 247,511 36,898,548 Total convertible preferred stock 121,434,713 112,088,065 $ 448,312 $ 450,850 115,598,018

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Summary of Stock-based Compensation Expenses	The following table presents the classification of stock-based compensation expense for stock options and restricted stock units (RSUs) for employees and non-employees within the Condensed Consolidated Statements of Operations and Comprehensive Loss: Three months ended June 30, Six months ended June 30, (in thousands) 2021 2020 2021 2020 Research and development $ 1,067 $ 288 $ 1,696 $ 976 General and administrative 3,910 481 4,980 1,058 Total $ 4,977 $ 769 $ 6,676 $ 2,034
Schedule of Share-based Payment Arrangement, Option, Activity	Stock option activity during the six months ended June 30, 2021 was as follows: (in thousands except share data) Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value Outstanding as of December 31, 2020 20,937,443 $ 1.85 8.5 $ 12,956 Granted 2,722,835 10.02 Cancelled (680,666) 2.28 Exercised (2,504,497) 1.18 9,629 Outstanding as of June 30, 2021 20,475,115 $ 2.84 8.6 $ 647,397 Exercisable as of June 30, 2021 7,146,350 $ 1.79 7.6 $ 213,533
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The following weighted-average assumptions were used to calculate the grant-date fair value of employee stock options: Six months ended June 30, 2021 2020 Expected term (in years) 6.2 6.2 Expected volatility 66 % 65 % Expected dividend yield — — Risk-free interest rate 0.97 % 1.00 %
Schedule of Nonvested RSU Activity	The following table summarizes Recursion’s RSU activity during the six months ended June 30, 2021: Stock units Weighted-average grant date fair value Outstanding as of December 31, 2020 — $ — Granted 76,762 30.42 Vested — — Forfeited — — Outstanding as of June 30, 2021 76,762 $ 30.42
Schedule of Share-based Payment, Award, ESPP, Valuation Assumptions	The weighted-average assumptions used in the Black-Scholes models were as follows: Three months ended Six months ended June 30, 2021 Expected term (in years) 0.6 0.6 Expected volatility 69 % 69 % Expected dividend yield — — Risk-free interest rate 0.04 % 0.04 %
Summary Of Changes In Company's Warrant Liability	The following is a summary of the changes in the Company’s Series A and B warrant liability balance during the six months ended June 30, 2021 and 2020: (in thousands) Balance as of December 31, 2019 $ 128 Net increase in fair value of warrants 5 Balance as of June 30, 2020 $ 133 Balance as of December 31, 2020 $ 125 Increase in fair value of warrants 2,215 Recorded in equity upon exercise (2,340) Balance as of June 30, 2021 $ —

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss per Share	The following tables set forth the computation of basic and diluted net loss per share of Class A and Class B common stock during 2021: Three months ended Six months ended June 30, 2021 June 30, 2021 (in thousands, except share amount) Class A Class B Class A Class B Numerator: Allocation of undistributed earnings $ (40,432) $ (2,970) $ (65,457) $ (8,661) Denominator: Weighted average common shares outstanding 128,892,763 9,467,883 71,554,357 9,467,883 Net loss per share, basic and diluted $ (0.31) $ (0.31) $ (0.91) $ (0.91) The following table sets forth the computation of basic and diluted net loss per share during 2020: Three months ended Six months ended (in thousands, except share amounts) June 30, 2020 Numerator: Net loss $ (18,943) $ (37,367) Denominator: Weighted average common shares outstanding 21,652,277 21,646,118 Net loss per share, basic and diluted $ (0.88) $ (1.73)
Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share	The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: Three months ended Six months ended June 30, 2021 June 30, 2021 Class A Class B Class A Class B Convertible preferred stock 25,406,158 — 70,001,023 — Stock options and RSUs 17,115,903 — 15,445,067 — Warrants 178,208 — 193,773 — ESPP 13,334 — — — Total 42,713,603 — 85,639,863 — The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: Three months ended Six months ended June 30, 2020 Convertible preferred stock 78,699,470 78,699,470 Stock options 4,557,396 4,087,585 Warrants 194,037 183,807 Total 83,450,903 82,970,862

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables summarize the Company’s assets and liabilities that are measured at fair value on a recurring basis: Basis of fair value measurement (in thousands) June 30, 2021 Level 1 Level 2 Level 3 Assets Cash and equivalents $ 632,738 $ 632,738 $ — $ — Restricted cash 10,232 10,232 — — Total assets $ 642,970 $ 642,970 $ — $ — Basis of fair value measurement (in thousands) December 31, 2020 Level 1 Level 2 Level 3 Assets Cash and equivalents $ 262,126 $ 262,126 $ — $ — Restricted cash 5,041 5,041 — — Total assets $ 267,167 $ 267,167 $ — $ — Liabilities Warrant liability $ 125 $ — $ — $ 125 Total liabilities $ 125 $ — $ — $ 125
Fair Value Disclosure of Asset and Liability Not Measured at Fair Value	The following tables summarize the Company’s financial instruments that are not measured at fair value: Book values Fair values (in thousands) June 30, 2021 December 31, 2020 June 30, 2021 December 31, 2020 Liabilities Current portion of notes payable $ 3,135 $ 1,073 $ 3,135 $ 1,073 Notes payable, net of current portion 9,423 11,414 9,423 11,414 Total liabilities $ 12,558 $ 12,487 $ 12,558 $ 12,487

Description of the Business (De

Description of the Business (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 287,719	$ 213,601

Basis of Presentation (Details)

Basis of Presentation (Details)	Apr. 09, 2021	Apr. 30, 2021
Class of Stock [Line Items]
Stock split, conversion ratio	1.5	1.5
Common Stock (Class A and B)
Class of Stock [Line Items]
Stock split, conversion ratio		1

Supplemental Financial Inform_3

Supplemental Financial Information - PPE (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 62,306		$ 62,306		$ 35,929
Less: Accumulated depreciation	(13,757)		(13,757)		(9,962)
Property and equipment, net	48,549		48,549		25,967
Depreciation	2,400	$ 1,000	3,800	$ 2,000
Lab equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	25,562		25,562		19,701
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	13,312		13,312		13,792
Office equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	20,005		20,005		1,075
Property and equipment additions			17,900
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,427		$ 3,427		$ 1,361

Supplemental Financial Inform_4

Supplemental Financial Information - Accruals (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Supplemental Financial Information [Abstract]
Accrued compensation	$ 4,396	$ 3,085
Accrued development expenses	2,895	2,289
Accrued early discovery expenses	1,113	338
Accrued other expenses	4,306	4,773
Accrued expenses and other liabilities	$ 12,710	$ 10,485

Supplemental Financial Inform_5

Supplemental Financial Information - Interest (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Supplemental Financial Information [Abstract]
Interest expense	$ 2,501	$ 426	$ 2,750	$ 727
Interest income	(29)	(24)	(45)	(244)
Interest expense, net	$ 2,472	$ 402	$ 2,705	$ 483

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 801,000	$ 0	$ 801,000	$ 0
Goodwill impairment			0
Gross carrying amount	911,000		911,000		$ 911,000
Accumulated Amortization	(278,000)		(278,000)		(127,000)
Net carrying amount	633,000	0	633,000	0	784,000
Indefinite-lived intangible asset	904,000		904,000		904,000
Intangible assets, gross	1,815,000		1,815,000		1,815,000
Intangible assets, net	1,537,000		1,537,000		$ 1,688,000
Amortization expense	76,000	$ 0	152,000	$ 0
Impairment of definite-lived intangible assets	0		0
Impairment of indefinite-lived intangible assets	$ 0		$ 0

Notes Payable - Midcap Financia

Notes Payable - Midcap Financial (Details) $ in Thousands	1 Months Ended	6 Months Ended	12 Months Ended
	Sep. 30, 2019USD ($)	Jun. 30, 2021USD ($)monthlyPayment	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)
Midcap loan agreement, tranche 1 | Line of credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 11,900
Midcap loan agreement, tranche 2 | Line of credit
Debt Instrument [Line Items]
Maximum borrowing capacity	15,000
Midcap loan agreement | Line of credit
Debt Instrument [Line Items]
Maximum borrowing capacity	26,900
Line of credit outstanding		$ 11,900		$ 11,900
Debt instrument, number of periodic payments | monthlyPayment		36
Debt instrument, periodic payment, principal		$ 330
Debt instrument, additional interest only period		12 months
Interest rate increase in case of contract breach		2.00%
Payments of fees in connection with the midcap loan agreement			$ 298
Midcap loan agreement | Line of credit | London Interbank Offered Rate (LIBOR) | Minimum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		2.00%
Midcap loan agreement | Line of credit | London Interbank Offered Rate (LIBOR) | Maximum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		5.75%
Pacific Western Bank loan | Loans payable
Debt Instrument [Line Items]
Repayments of debt	$ 11,200

Notes Payable - Pacific Western

Notes Payable - Pacific Western (Details) - Letter of credit - Pacific Western letter of credit - USD ($) $ in Millions	Dec. 31, 2020	May 31, 2018
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 3.8
Line of credit outstanding	$ 3.8
Restricted cash	$ 4

Notes Payable - Convertible Not

Notes Payable - Convertible Notes (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2020
Debt Instrument [Line Items]
Shares issued in the period, upon conversion (in shares)	1,203,231
Stock issued during the period, value of conversion of convertible securities	$ 1,600
Convertible notes payable
Debt Instrument [Line Items]
Debt instrument, face amount		$ 6,400	$ 6,400
Change in fair value of derivate		$ (323)	$ (323)

Notes Payable - Notes Payable f

Notes Payable - Notes Payable for Tenant Improvement Allowance (Details) - Notes payable - Station 41 lease $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of long-term debt	$ 992
Debt instrument, term	10 years
Debt Instrument, interest rate	8.00%

Notes Payable - Current_Noncurr

Notes Payable - Current/Noncurrent (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Total liabilities	$ 12,661
Notes payable
Debt Instrument [Line Items]
Current portion of notes payable	3,135	$ 1,073
Notes payable, net of current portion	9,595	11,615
Less: unamortized issuance costs	(172)	(201)
Total liabilities	$ 12,558	$ 12,487

Notes Payable - Principal Repay

Notes Payable - Principal Repayments (Details) $ in Thousands	Jun. 30, 2021USD ($)
Debt Disclosure [Abstract]
2021	$ 1,033
2022	4,052
2023	4,059
2024	3,059
2025	112
Thereafter	346
Total liabilities	$ 12,661

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 31, 2021USD ($)ft²	Aug. 31, 2017extensionPeriod	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019	Aug. 31, 2019	Dec. 31, 2017USD ($)	Aug. 31, 2016USD ($)
Lessee, Lease, Description [Line Items]
Rent expense			$ 1,400	$ 1,100	$ 2,700	$ 2,100
Station 41
Lessee, Lease, Description [Line Items]
Lease term	10 years							7 years
Incentive from lessor	$ 10,100
Size of additional leased asset | ft²	91,478
Total minimum payments	$ 32,400
Milpitas
Lessee, Lease, Description [Line Items]
Lease term									9 years
Station 41 lease | Notes payable
Lessee, Lease, Description [Line Items]
Proceeds from issuance of long-term debt							$ 992
Debt Instrument, interest rate							8.00%
Komas
Lessee, Lease, Description [Line Items]
Lease term											7 years
Incentive from lessor											$ 847
Lease incentive, payable			313		313
Station 41
Lessee, Lease, Description [Line Items]
Lease term		10 years
Incentive from lessor										$ 4,000
Lease incentive, payable			$ 2,600		$ 2,600
Number of renewal options (in extension periods) | extensionPeriod		1
Operating lease, renewal term		5 years

Commitments and Contingencies_2

Commitments and Contingencies - Minimum payments (Details) $ in Thousands	Jun. 30, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021	$ 1,952
2022	4,963
2023	7,344
2024	7,371
2025	7,560
Thereafter	33,214
Total Minimum Payments	$ 62,404

Convertible Preferred Stock - N

Convertible Preferred Stock - Narrative (Details) - shares	1 Months Ended
	Apr. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Preferred Units [Line Items]
Shares issued in the period, upon conversion (in shares)		1,203,231
Convertible preferred stock, shares outstanding (in shares)			0	112,088,065	112,088,065	75,189,517	75,189,517	75,189,517
IPO
Preferred Units [Line Items]
Shares issued in the period, upon conversion (in shares)	115,598,018

Convertible Preferred Stock - S

Convertible Preferred Stock - Summary (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Preferred Units [Line Items]
Preferred shares authorized (in shares)	200,000,000		121,434,713
Preferred shares issued (in shares)	0		112,088,065
Preferred shares outstanding (in shares)	0	112,088,065	112,088,065	75,189,517	75,189,517	75,189,517
Carrying Value	$ 0	$ 448,312	$ 448,312	$ 201,109	$ 201,109	$ 201,109
Liquidation Preferences	$ 0		$ 450,850
Shares of common stock issuable upon conversion (in shares)			115,598,018
Series A
Preferred Units [Line Items]
Preferred shares authorized (in shares)			30,078,402
Preferred shares issued (in shares)			29,965,754
Preferred shares outstanding (in shares)			29,965,754
Carrying Value			$ 21,281
Liquidation Preferences			$ 21,281
Shares of common stock issuable upon conversion (in shares)			29,965,754
Series A-1
Preferred Units [Line Items]
Preferred shares authorized (in shares)			4,975,521
Preferred shares issued (in shares)			4,975,520
Preferred shares outstanding (in shares)			4,975,520
Carrying Value			$ 0
Liquidation Preferences			$ 0
Shares of common stock issuable upon conversion (in shares)			4,975,520
Series B
Preferred Units [Line Items]
Preferred shares authorized (in shares)			21,497,667
Preferred shares issued (in shares)			21,471,898
Preferred shares outstanding (in shares)			21,471,898
Carrying Value			$ 59,913
Liquidation Preferences			$ 60,000
Shares of common stock issuable upon conversion (in shares)			21,471,898
Series C
Preferred Units [Line Items]
Preferred shares authorized (in shares)			18,956,354
Preferred shares issued (in shares)			18,776,345
Preferred shares outstanding (in shares)			18,776,345
Carrying Value			$ 119,915
Liquidation Preferences			$ 122,058
Shares of common stock issuable upon conversion (in shares)			22,286,298
Series D
Preferred Units [Line Items]
Preferred shares authorized (in shares)			45,926,769
Preferred shares issued (in shares)			36,898,548
Preferred shares outstanding (in shares)			36,898,548
Carrying Value			$ 247,203
Liquidation Preferences			$ 247,511
Shares of common stock issuable upon conversion (in shares)			36,898,548

Common Stock - Narrative (Detai

Common Stock - Narrative (Details) $ / shares in Units, $ in Millions	Apr. 20, 2021USD ($)$ / sharesshares	Apr. 09, 2021	Apr. 30, 2021shares	Sep. 30, 2020shares	Jun. 30, 2021vote
Class of Stock [Line Items]
Shares issued in the period, upon conversion (in shares) | shares				1,203,231
Stock split, conversion ratio		1.5	1.5
Class A
Class of Stock [Line Items]
Vote per share of common stock (in votes) | vote					1
Class B
Class of Stock [Line Items]
Vote per share of common stock (in votes) | vote					10
Christopher Gibson and his affiliates
Class of Stock [Line Items]
Affiliated holders, ownership percentage					0.38
Affiliated holders, potential ownership percentage when outstanding equity awards vest					0.41
IPO
Class of Stock [Line Items]
IPO, number of shares issued | shares	27,878,787
Price per share | $ / shares	$ 18
IPO, net proceeds received | $	$ 462.4
IPO, underwriting discounts and commissions | $	35.1
IPO, expenses costs | $	$ 4.3
Shares issued in the period, upon conversion (in shares) | shares			115,598,018

Collaborative and Other Resea_2

Collaborative and Other Research and Development Contracts - Bayer AG (Details) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Aug. 31, 2020USD ($)project	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Current portion of unearned revenue		$ 10,000	$ 10,000	$ 10,000
Unearned revenue, net of current portion		11,667	11,667	$ 16,667
Bayer AG | Collaborative arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, term	5 years
Number of projects that may be initiated (in projects) | project	10
Non-refundable upfront payment received	$ 30,000
Revenue from contract with customer		2,500	5,000
Current portion of unearned revenue		10,000	10,000
Unearned revenue, net of current portion		$ 11,700	$ 11,700
Research project, fees and milestones payments receivable for an option on a lead series	100,000
Research project, fees and milestones payments receivable for an option on a development candidate	$ 120,000

Collaborative and Other Resea_3

Collaborative and Other Research and Development Contracts - The National Institute of Health (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2018	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from grants	$ 2,549	$ 186	$ 5,111	$ 246
Grant revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from grants	49	186	111	246
The National Institute Of Health | Collaborative arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, potential funding					$ 1,400
Collaborative agreement, potential funding remaining	346		346
Grants receivable	49		49			$ 140
The National Institute Of Health | Collaborative arrangement | Grant revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from grants	$ 49	$ 186	$ 111	$ 246

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payment arrangement, expense	$ 4,977	$ 769	$ 6,676	$ 2,034
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payment arrangement, expense	1,067	288	1,696	976
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payment arrangement, expense	$ 3,910	$ 481	$ 4,980	$ 1,058

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 30, 2021	Feb. 28, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2017	Mar. 31, 2020	Aug. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted in period, weighted average grant date fair value (in dollars per share)					$ 5.96	$ 1.49
Options, granted in period (in shares)					2,722,835
Options, outstanding, number (in shares)			20,475,115		20,475,115		20,937,443
Share-based payment arrangement, expense			$ 4,977,000	$ 769,000	$ 6,676,000	$ 2,034,000
Unvested stock options, unamortized stock-based compensation cost			$ 28,600,000		$ 28,600,000
Unvested stock options, unamortized stock-based compensation cost, weighted average period recognition					3 years
Share-based Payment Arrangement, Nonemployee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, granted in period (in shares)			0	0	0	0	120,000	330,000
Performance shares | Share-based Payment Arrangement, Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, granted in period (in shares)		150,000
Options, granted in period, fair value		$ 358,000
Options, outstanding, number (in shares)									1,500,000
Options, outstanding, estimated fair value at grand date									$ 2,000,000
Share-based payment arrangement, expense			$ 1,600,000	$ 0	$ 1,600,000	$ 0
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost			2,100,000		$ 2,100,000
Unvested stock options, unamortized stock-based compensation cost, weighted average period recognition					2 years 9 months
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, vesting period	4 years
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, vesting period					4 years
Stock options, expiration period					10 years
Share-based payment arrangement, expense			216,000		$ 216,000
Unvested stock options, unamortized stock-based compensation cost, weighted average period recognition					5 months
Shares issued during the period (in shares)					0
Unrecognized compensation cost			$ 407,000		$ 407,000
Key personnel incentive plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)			0		0
2016 Equity incentive plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)			0		0
Common stock, capital shares reserved for future issuance (in shares)										25,686,958
2021 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)			15,507,871		15,507,871
Common stock, capital shares reserved for future issuance (in shares)	16,186,000
ESPP | ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)	3,238,000
Purchase period	6 months
Purchase price of common stock (as a percent)	85.00%

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Share-based Payment Arrangement, Option, Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options, outstanding, number at beginning of period (in shares) | shares	20,937,443
Options, granted in period (in shares) | shares	2,722,835
Options, cancelled in period (in shares) | shares	(680,666)
Options, exercised in period (in shares) | shares	(2,504,497)
Options, outstanding, number at end of period (in shares) | shares	20,475,115	20,937,443
Options, exercisable, number (in shares) | shares	7,146,350
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Options, outstanding, weighted average exercise price at beginning of period (in dollars per share) | $ / shares	$ 1.85
Options, grants in period, weighted average exercise price (in dollars per share) | $ / shares	10.02
Options, cancelled in period, weighted average exercise price (in dollars per share) | $ / shares	2.28
Options, exercised in period, weighted average exercise price (in dollars per share) | $ / shares	1.18
Options, outstanding, weighted average exercise price at end of period (in dollars per share) | $ / shares	2.84	$ 1.85
Options, exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 1.79
Options, outstanding, weighted average remaining contractual life	8 years 7 months 6 days	8 years 6 months
Options, exercisable, weighted average remaining contractual life	7 years 7 months 6 days
Options, outstanding, intrinsic value | $	$ 647,397	$ 12,956
Options, exercised in period, intrinsic value | $	9,629
Options, exercisable, intrinsic value | $	$ 213,533

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumption (Details) - Stock options	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 2 months 12 days	6 years 2 months 12 days
Expected volatility	66.00%	65.00%
Expected dividend yield	0.00%	0.00%
Risk-free interest rate	0.97%	1.00%

Stock-Based Compensation - Warr

Stock-Based Compensation - Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Jan. 31, 2020	Jun. 30, 2021	Dec. 31, 2020
Warrants Issued In January 2020 | Series C
Warrants Arrangements [Line Items]
Warrants outstanding (in shares)		170,000
Warrants, exercise price (in dollars per share)	$ 6.51
Warrants issued (in shares)	180,000
Warrants, vesting period	18 months
Warrants, grand date fair value (in dollars per share)		$ 4.10
Unvested warrants, unamortized stock-based compensation cost		$ 35
Unvested warrants, unamortized stock-based compensation cost, weighted average period recognition		1 month
2016 Warrants
Warrants Arrangements [Line Items]
Warrants outstanding (in shares)			84,486
Warrants, exercise price (in dollars per share)			$ 0.71
2017 Warrants
Warrants Arrangements [Line Items]
Warrants outstanding (in shares)			28,161
Warrants, exercise price (in dollars per share)			$ 0.71
Warrants, fair value			$ 77
2018 Warrants
Warrants Arrangements [Line Items]
Warrants outstanding (in shares)			25,762
Warrants, exercise price (in dollars per share)			$ 2.79
Warrants, fair value			$ 48

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of RSU Activity (Details) - Restricted stock	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Stock units
Beginning balance, outstanding (in shares) | shares	0
Granted (in shares) | shares	76,762
Vested (in shares) | shares	0
Forfeited (in shares) | shares	0
Ending balance, outstanding (in shares) | shares	76,762
Weighted-average grant date fair value
Beginning balance, outstanding Weighted average grant date fair value (in dollars per share) | $ / shares	$ 0
Granted (in dollars per share) | $ / shares	30.42
Vested (in dollars per share) | $ / shares	0
Forfeited (in shares) | $ / shares	0
Ending balance, outstanding Weighted average grant date fair value (in dollars per share) | $ / shares	$ 30.42

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Share-based Payment, Award, ESPP, Valuation Assumptions (Details) - ESPP	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021
Warrants Arrangements [Line Items]
Expected term (in years)	7 months 6 days	7 months 6 days
Expected volatility	69.00%	69.00%
Expected dividend yield	0.00%	0.00%
Risk-free interest rate	0.04%	0.04%

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Warrants Outstanding (Details) $ / shares in Units, $ in Thousands	Dec. 31, 2020USD ($)$ / sharesshares
2016 Warrants
Warrants Arrangements [Line Items]
Warrants outstanding (in shares) | shares	84,486
Warrants, exercise price (in dollars per share) | $ / shares	$ 0.71
2017 Warrants
Warrants Arrangements [Line Items]
Warrants outstanding (in shares) | shares	28,161
Warrants, exercise price (in dollars per share) | $ / shares	$ 0.71
Warrants, fair value | $	$ 77
2018 Warrants
Warrants Arrangements [Line Items]
Warrants outstanding (in shares) | shares	25,762
Warrants, exercise price (in dollars per share) | $ / shares	$ 2.79
Warrants, fair value | $	$ 48

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary Of Changes In Company's Warrant Liability (Details) - Warrants - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value of warrants at beginning of period	$ 125	$ 128
Net increase in fair value of warrants	2,215	5
Recorded in equity upon exercise	(2,340)
Fair value of warrants at end of period	$ 0	$ 133

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Retirement Benefits [Abstract]
Employee benefit plan, percentage of maximum annual contributions per employee			4.00%
Employee benefit plan, percentage of matching contribution			100.00%
Employee benefit plan, employer matching contribution, percentage of employees' gross pay			4.00%
Employee benefit plan, employer expenses	$ 372	$ 201	$ 653	$ 400

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0	$ 0	$ 0

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Undistributed earnings, basic	$ (40,432)
Undistributed earnings, diluted	$ (2,970)		$ (65,457)
Denominator:
Weighted average common shares outstanding, basic (in shares)	138,360,646	21,652,277	81,022,240	21,646,118
Weighted average common shares outstanding, diluted (in shares)	138,360,646	21,652,277	81,022,240	21,646,118
Net loss per share, basic (in dollars per shares)	$ (0.31)	$ (0.88)	$ (0.91)	$ (1.73)
Net loss per share, diluted (in dollars per shares)	$ (0.31)	$ (0.88)	$ (0.91)	$ (1.73)
Class A
Numerator:
Undistributed earnings, basic			$ (65,457)
Undistributed earnings, diluted	$ (40,432)
Denominator:
Weighted average common shares outstanding, basic (in shares)	128,892,763		71,554,357
Weighted average common shares outstanding, diluted (in shares)	128,892,763		71,554,357
Net loss per share, basic (in dollars per shares)	$ (0.31)		$ (0.91)
Net loss per share, diluted (in dollars per shares)	$ (0.31)		$ (0.91)
Class B
Numerator:
Undistributed earnings, basic	$ (2,970)		$ (8,661)
Undistributed earnings, diluted			$ (8,661)
Denominator:
Weighted average common shares outstanding, basic (in shares)	9,467,883		9,467,883
Weighted average common shares outstanding, diluted (in shares)	9,467,883		9,467,883
Net loss per share, basic (in dollars per shares)	$ (0.31)		$ (0.91)
Net loss per share, diluted (in dollars per shares)	$ (0.31)		$ (0.91)

Net Loss Per Share - Schedule_2

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)		83,450,903		82,970,862
Class A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)	42,713,603		85,639,863
Class B
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)	0		0
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)		78,699,470		78,699,470
Convertible preferred stock | Class A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)	25,406,158		70,001,023
Convertible preferred stock | Class B
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)	0		0
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)		4,557,396		4,087,585
Stock options and RSUs | Class A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)	17,115,903		15,445,067
Stock options and RSUs | Class B
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)	0		0
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)		194,037		183,807
Warrants | Class A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)	178,208		193,773
Warrants | Class B
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)	0		0
ESPP | Class A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)	13,334		0
ESPP | Class B
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of loss per share, amount (in shares)	0		0

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) $ in Millions	Dec. 31, 2020USD ($)
Letter of credit | Pacific Western letter of credit
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Restricted cash	$ 4

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and equivalents	$ 632,738	$ 262,126
Restricted cash	10,232	5,041
Total assets	642,970	267,167
Warrant liability		125
Total liabilities		125
Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and equivalents	632,738	262,126
Restricted cash	10,232	5,041
Total assets	642,970	267,167
Warrant liability		0
Total liabilities		0
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and equivalents	0	0
Restricted cash	0	0
Total assets	0	0
Warrant liability		0
Total liabilities		0
Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and equivalents	0	0
Restricted cash	0	0
Total assets	$ 0	0
Warrant liability		125
Total liabilities		$ 125

Fair Value Measurements - Ass_2

Fair Value Measurements - Asset and Liability Not Measured at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Notes payable
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Current portion of notes payable	$ 3,135	$ 1,073
Notes payable, net of current portion	9,595	11,615
Book values
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Total liabilities	12,558	12,487
Book values | Notes payable
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Current portion of notes payable	3,135	1,073
Notes payable, net of current portion	9,423	11,414
Fair values
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Total liabilities	12,558	12,487
Fair values | Notes payable
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Current portion of notes payable	3,135	1,073
Notes payable, net of current portion	$ 9,423	$ 11,414

Related Party Transactions (Det

Related Party Transactions (Details) - Chief Executive Officer - USD ($)	Dec. 05, 2017	Jun. 30, 2021	Jun. 30, 2020
Related Party Transaction [Line Items]
Loan to related party	$ 595,000	$ 0	$ 0
Debt instrument, term	7 years

Subsequent Events (Details)

Subsequent Events (Details) $ in Millions	1 Months Ended
	Jul. 31, 2021USD ($)
Subsequent Event | Midcap loan agreement | Line of credit
Subsequent Event [Line Items]
Repayments of debt	$ 12.7